REFERENCES
- Goldenberg D, editor. Cancer therapy with radiolabeled anti-bodies. London: CRC Press, 1995: 1–314.
- Hutter RVP, editor-in-chief. Sixth Conference on Radioim-munodetection and Radioimmunotherapy of Cancer: 1996 Oct 10–12; Princeton, New Jersey. Cancer 1997; 80 (Suppl 12): 2343–54.
- Larsson LG, Einhom J, Vinnsland S, Overgaard J, Teppo L, editors. 3rd Scandinavian symposium on radiolabeled mono-clonal antibodies for cancer diagnosis and therapy: 1992 Oct 30-31; Helsinki, Finland. Acta Oncol 1993; 32: 707–891.
- Blumenthal R, Sharkey R, Forman D, Wong G, Goldenberg D. Cytokine intervention permits dose escalation of radioanti-body: an analysis of myelostimulation by bolus vs continuous infusion of IL-1/GM-CSF. Cancer 1994; 73: 1083–92.
- Kuhn J, Beatty B, Wong J, et al. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1995; 51: 2335–9.
- Marshall D, Pedley R, Melton R, Boden J, Boden R, Begent R. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab'), fragments of an anti-tumor antibody. Br J Cancer 1995; 71: 18–24.
- Zlotecki R, Boucher Y, Lee I, Baxter LT, Jain RK. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res 1993; 53: 2466–8.
- Pedley B, Boden J, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996; 56: 3293–300.
- Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990; 18: 1261–9.
- Sundström B, Nathrath WBJ, Stigbrand T. Diversity in im-munoreactivity of tumor-derived cytokeratin monoclonal anti-bodies. J Histochem Cytochem 1989; 37: 1845–54.
- Greenwood F, Hunter W, Glover J. The preparation of 'I-labeled human growth hormone of high specific radioac-tivity. J Biochem 1963; 89: 114–23.
- Laemmli U. Cleavage of structural proteins during the assem-bly of the head of bacteriophage T4. Nature 1970; 227: 680–5.
- Ellet WH, Humes RM. Absorbed fractions for small volumes containing photonemitting radioactivity. MIRD Pamphlet no 8. J Nucl Med 1971; 5 (Suppl): 25–32.
- Kishore R, Eary JF, Krohn KA, et al. Autoradiolysis of iodinated monoclonal antibody preparations. Nucl Med Biol 1986; 4: 457–9.
- Chakrabarti MC, Le N, Paik CH, De Graff WG, Carrasquillo JA. Prevention of radiolysis of monoclonal antibody during labeling. J Nucl Med 1996; 8: 1384–8.
- Wahl RL, Wissing J, del Rosario R, Zasadny KR. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 1990; 1: 84–9.
- Ullen A, Sandstrom P, Riklund kfistrom K, et al. Use of anticytokeratin monoclonal anti-idiotypic antibodies to im-prove tumor:non-tumor ratio in experimental radioimmunolo-calization. Cancer Res 1995; 55: 5868s–73s.
- Garkavij M, Tennvall J, Strand S-E, et al. Enhanced radioim-munotargeting of 124-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats. Cancer Res 1995; 55: (Suppl) 5874s–80s.
- Garkavij M, Tennvall J, Strand S-E, et al. Extracorporeal immunoadsorption from whole blood based on the avidin-bi-otin concept: evaluation of a new method. Acta Oncol 1996; 35: 309–12.